ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,245.37
-0.48%
Dow Jones
38,798.99
-0.22%
Gold vs US Dollar
2,293.845
0.00%
Brent Oil
79.395
0.00%
Bitcoin
69,260.17
-0.07%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Blueprint Medicines Corporation (BPMC)

  7. Blueprint Medicines Corporation (BPMC) News

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BPMC
DateTimeSourceHeadlineSymbolCompany
07/06/202421:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
06/06/202421:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
05/06/202422:11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
05/06/202421:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
04/06/202421:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
04/06/202421:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
03/06/202421:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
31/05/202421:38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
30/05/202423:01PR Newswire (US)Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)NASDAQ:BPMCBlueprint Medicines Corporation
24/05/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPMCBlueprint Medicines Corporation
23/05/202422:05PR Newswire (US)Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
17/05/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
17/05/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
15/05/202422:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
15/05/202422:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
10/05/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
06/05/202422:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
06/05/202422:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
06/05/202421:01PR Newswire (US)Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BPMCBlueprint Medicines Corporation
02/05/202412:00PR Newswire (US)Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceNASDAQ:BPMCBlueprint Medicines Corporation
18/04/202413:00PR Newswire (US)Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024NASDAQ:BPMCBlueprint Medicines Corporation
11/04/202413:00PR Newswire (US)Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsNASDAQ:BPMCBlueprint Medicines Corporation
04/04/202421:01PR Newswire (US)Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BPMCBlueprint Medicines Corporation
11/03/202422:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202422:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202422:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202422:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202422:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202422:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
11/03/202422:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
 Showing the most relevant articles for your search:NASDAQ:BPMC

Your Recent History

USOTC
SNEHF
Snack Empire (PK)
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved